14.90
price up icon2.83%   0.41
after-market After Hours: 14.90
loading
Pliant Therapeutics Inc stock is traded at $14.90, with a volume of 280.96K. It is up +2.83% in the last 24 hours and up +29.23% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$14.49
Open:
$14.43
24h Volume:
280.96K
Relative Volume:
0.75
Market Cap:
$905.94M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-5.438
EPS:
-2.74
Net Cash Flow:
$-139.79M
1W Performance:
+1.22%
1M Performance:
+29.23%
6M Performance:
+6.58%
1Y Performance:
-7.51%
1-Day Range:
Value
$14.12
$15.07
1-Week Range:
Value
$14.00
$15.25
52-Week Range:
Value
$10.22
$19.62

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Name
Pliant Therapeutics Inc
Name
Phone
650-481-6770
Name
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
166
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PLRX's Discussions on Twitter

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-18-23 Initiated Canaccord Genuity Buy
Apr-13-23 Initiated Robert W. Baird Outperform
Dec-14-22 Initiated Stifel Buy
Dec-07-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Buy
Jul-20-22 Initiated SVB Leerink Outperform
May-25-22 Initiated Cantor Fitzgerald Overweight
Dec-10-21 Initiated Oppenheimer Outperform
Nov-24-21 Initiated RBC Capital Mkts Outperform
Nov-03-21 Initiated H.C. Wainwright Buy
Apr-20-21 Initiated BTIG Research Buy
Apr-05-21 Initiated Citigroup Buy
Jun-29-20 Initiated Citigroup Buy
Jun-29-20 Initiated Cowen Outperform
Jun-29-20 Initiated Needham Buy
Jun-29-20 Initiated Piper Sandler Overweight
View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

pulisher
Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Nov 03, 2024
pulisher
Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 03, 2024
pulisher
Oct 21, 2024

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire

Oct 17, 2024
pulisher
Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance

Oct 17, 2024
pulisher
Oct 15, 2024

Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

How To Trade (PLRX) - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance

Oct 04, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 02, 2024
pulisher
Oct 01, 2024

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire

Oct 01, 2024
pulisher
Oct 01, 2024

Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail

Oct 01, 2024
pulisher
Oct 01, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World

Oct 01, 2024
pulisher
Sep 30, 2024

Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian

Sep 30, 2024
pulisher
Sep 30, 2024

11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World

Sep 30, 2024
pulisher
Sep 28, 2024

Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa

Sep 28, 2024
pulisher
Sep 27, 2024

Pliant Therapeutics updates bylaws, aligns with Delaware law - Investing.com

Sep 27, 2024
pulisher
Sep 25, 2024

Investing in Pliant Therapeutics Inc (PLRX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Pliant Therapeutics Inc (PLRX) receives an Outperform rating from Leerink Partners - Knox Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Pharma stock to buy now for an upside of 20%; Are you holding it? - Trade Brains

Sep 25, 2024
pulisher
Sep 25, 2024

5,372 Shares in Piper Sandler Companies (NYSE:PIPR) Purchased by Intech Investment Management LLC - MarketBeat

Sep 25, 2024
pulisher
Sep 24, 2024

Berkley W R Corp Cuts Stock Position in Plum Acquisition Corp. I (NASDAQ:PLMI) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Raises Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Priority Technology (NASDAQ:PRTH) Reaches New 1-Year High After Analyst Upgrade - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

First Light Asset Management LLC Sells 133,780 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Palfinger (OTCMKTS:PLFRY) Trading Down 2% - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Pulse Biosciences (NASDAQ:PLSE) Shares Down 5.4% - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Pulse Biosciences Inc [PLSE] Investment Appeal on the Rise - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily

Sep 23, 2024
pulisher
Sep 23, 2024

Rhumbline Advisers Raises Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

Inspire Investing LLC Sells 8,725 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to "Sell" - MarketBeat

Sep 21, 2024
pulisher
Sep 21, 2024

Piper Sandler Companies (NYSE:PIPR) Shares Acquired by Commonwealth Equity Services LLC - Defense World

Sep 21, 2024
pulisher
Sep 19, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World

Sep 19, 2024

Pliant Therapeutics Inc Stock (PLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Pliant Therapeutics Inc Stock (PLRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Hull Hans
Chief Business Officer
Jul 10 '24
Sale
11.56
9,900
114,444
227,494
Cummings Keith Lamont
Chief Financial Officer
Jul 10 '24
Sale
11.56
10,911
126,131
282,115
Coulie Bernard
President and CEO
Jul 10 '24
Sale
11.56
38,710
447,488
482,936
Ouimette Mike
General Counsel & Corp. Sec'y
Jul 10 '24
Sale
11.56
7,656
88,503
94,044
Cummings Keith Lamont
Chief Financial Officer
May 02 '24
Option Exercise
2.08
21,000
43,680
271,713
Cummings Keith Lamont
Chief Financial Officer
Jan 17 '24
Sale
17.23
9,781
168,527
194,605
Hull Hans
Chief Business Officer
Jan 17 '24
Sale
17.23
9,786
168,613
185,069
Coulie Bernard
President and CEO
Jan 17 '24
Sale
17.23
25,721
443,173
316,382
Lefebvre Eric
Chief Medical Officer
Jan 17 '24
Sale
17.23
10,295
177,383
156,920
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 17 '24
Sale
17.23
5,197
89,544
55,246
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):